RecruitingPhase 2NCT07467993

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)

Sponsor

Novartis Pharmaceuticals

Enrollment

142 participants

Start Date

Mar 16, 2026

Study Type

INTERVENTIONAL

Conditions

Schizophrenia

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GXV813 and a drug called Placebo for people with schizophrenia. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGXV813

GXV813 administered orally.

DRUGPlacebo

Placebo administered orally.

Locations(7)

Pillar Clinical Research LLC

Bentonville, Arkansas, United States

CNRI Los Angeles LLC

Pico Rivera, California, United States

Segal Institute for Clinical Research

Miami, Florida, United States

CenExel iResearch

Decatur, Georgia, United States

Uptown Research Institute LLC

Chicago, Illinois, United States

Pillar Clinical Research LLC

Chicago, Illinois, United States

Arch Clinical Trials LLC

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07467993

Related Trials

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT0710511122 locations

Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate

NCT063407891 location

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

NCT070612888 locations

Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial.

NCT050365901 location

French Source-monitoring Task

NCT042371551 location